Patent: 10,507,265
✉ Email this page to a colleague
Summary for Patent: 10,507,265
Title: | Cancellous bone product including viable osteogenic cells |
Abstract: | A bone implant comprising cancellous bone that is essentially free of blood cells, and which has been treated with at least a loosening agent, such as collagenase and/or a digestive enzyme, for a time and at a concentration to loosen the osteogenic cells in the cancellous bone matrix. The osteogenic cells in the matrix are viable cells. The treatment of the cancellous bone with at least one loosening agent enables the osteogenic cells to be more available for carrying out their osteogenic function and to provide for an increased rate of bone formation. |
Inventor(s): | Williams; Michelle LeRoux (Laurel, MD), Mills; Charles Randal (Finksburg, MD), Monroy; Rodney (Aberdeen, MD) |
Assignee: | NuVasive, Inc. (San Diego, CA) |
Application Number: | 15/596,237 |
Patent Claims: | see list of patent claims |
Details for Patent 10,507,265
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Smith & Nephew, Inc. | SANTYL | collagenase | Ointment | 101995 | 06/04/1965 | ⤷ Try a Trial | 2026-05-08 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |